Boston Scientific Corporation (NYSE:BSX) Short Interest Update

Boston Scientific Corporation (NYSE:BSX) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 57,491,117 shares, an increase of 83.0% from the May 14th total of 31,423,298 shares. Based on an average trading volume of 25,507,630 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.9% of the company’s shares are short sold.

Boston Scientific Trading Up 0.3%

Shares of NYSE BSX traded up $0.16 during midday trading on Tuesday, reaching $46.92. 11,140,183 shares of the stock were exchanged, compared to its average volume of 17,645,826. The company has a market capitalization of $69.74 billion, a price-to-earnings ratio of 19.63, a P/E/G ratio of 0.89 and a beta of 0.56. Boston Scientific has a 12 month low of $45.99 and a 12 month high of $109.50. The business has a 50-day simple moving average of $56.05 and a two-hundred day simple moving average of $74.40. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts expect that Boston Scientific will post 3.36 EPS for the current year.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BSX shares. Citigroup reduced their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, May 28th. Needham & Company LLC reissued a “buy” rating and set a $77.00 price target on shares of Boston Scientific in a research report on Monday, May 18th. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Stifel Nicolaus set a $75.00 price target on shares of Boston Scientific in a research report on Wednesday, May 27th. Finally, Piper Sandler reissued an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $85.08.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors have recently added to or reduced their stakes in BSX. Murphy & Mullick Capital Management Corp increased its stake in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the 4th quarter valued at $26,000. Finally, Colonial Trust Co SC increased its stake in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.